Tier 2 — strong

Quercetin reduces blood pressure in hypertensive subjects

Randi L Edwards, Tiffany Lyon, Sheldon E Litwin, Alexander Rabovsky, J David Symons, Thunder Jalili
The Journal of nutrition 2007 137(11):2405

Bibliography

PubMed
PMID 17951477
DOI
10.1093/jn/137.11.2405
Funding
Indexed grant support: 085226 — PHS HHS — United States. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled crossover trial
ModelHuman intervention research
Sample19 adults with prehypertension and 22 with stage 1 hypertension
InterventionQuercetin 730 mg/day or placebo
Duration28 days per intervention
EndpointsBlood pressure; Oxidative-stress measures

What the study showed, in plain terms

Published in 2007, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled crossover trial. Sample/model: 19 adults with prehypertension and 22 with stage 1 hypertension. The exposure or intervention was Quercetin 730 mg/day or placebo. Follow-up or treatment period: 28 days per intervention.

Blood pressure decreased in participants with stage 1 hypertension but not those with prehypertension; oxidative-stress measures did not improve.

Small short-term trial of surrogate outcomes. It does not establish prevention of cardiovascular events or equivalence to prescribed antihypertensive treatment.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Blood pressure decreased in participants with stage 1 hypertension but not those with prehypertension; oxidative-stress measures did not improve.
  • The recorded outcome domains were Blood pressure; Oxidative-stress measures.
  • The result applies to the tested exposure: Quercetin 730 mg/day or placebo; 28 days per intervention.

What this study can and cannot tell us

  • Small short-term trial of surrogate outcomes. It does not establish prevention of cardiovascular events or equivalence to prescribed antihypertensive treatment.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 2
Efficacy of quercetin and the role of endothelial protection in the treatment of patients with arterial hypertension
Valentyna Volodymyrivna Chopyak et al. · Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti · 2025
Tier 2
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN
Maryana I Prokosa et al. · Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2022
Tier 2
Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial
James I Dower et al. · The Journal of nutrition · 2015

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology